Business
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company
About this update from Black Diamond Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced forthcoming presentations during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 11-15, 2023. The three poster presentations include initial dose escalation data from the Company’s Phase 1 clinical trial of BDTX-1535 in non-small cell lung cancer (NSCLC), the study design of this ongoing Phase 1 clinical trial, and preclinical data for BDTX-4933. Details for the presentations are as follows: Title: Phase 1 Study of BDTX-1535, an Oral 4th Generation EGFR Inhibitor, in Patients with NSCLC andGBM: Preliminary Dose Escalation ResultsSpeaker: Helena Yu, M.D., Associate Attending Physician, Memorial Sloan Kettering Cancer Center Time: Poster Session C, Saturday, October 14, 12:30 pm-4:00 pmLocation/Poster #: Level 2, Exhibit Hall D, #C022 Title: A Phase 1 Study to Assess BDTX-1535, an Oral 4th Generation EGFR Inhibitor, in Patients with NSCLC and GBM Speaker: Helena Yu, M.D., Associate Attending Physician, Memorial Sloan Kettering Cancer CenterTime: Poster Session C, Saturday, October 14, 12:30 pm-4:00 pmLocation/Poster #: Level 2, Exhibit Hall D, #C036 Title: Preclinical Efficacy of BDTX-4933, a Brain-penetrant, Orthosteric RAF Inhibitor, Targeting Oncogenic RAF Conformation Shared by Groups of BRAF and Upstream Driver MutationsSpeaker: Elizabeth Buck, Ph.D., Chief Scientific Officer, Black Diamond Therapeutics Time: Poster Session A, Thursday, October 12, 12:30 pm-4:00 pmLocation/Poster #: Level 2, Exhibit Hall D, #A090 About BDTX-1535BDTX-1535 is a brain-penetrant and potent MasterKey inhibitor of oncogenic mutations of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC), including families of intrinsic driver mutations and acquired resistance C797S mutation that result post-treatment with osimertinib. While current treatments for NSCLC target singular mutations, BDTX-1535 has the potential to address approximately 50 different mutations across a diverse group of patients in multiple lines of therapy. BDTX-1535 also has the potential to treat patients with glioblastom...